alpha-MSH is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-30. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Solid peptide material is generally stable when kept cold and dry. Common practice is storage at -20 degrees Celsius or lower, with desiccant and protection from light. Repeated freeze-thaw cycles and exposure to moisture are associated with degradation, aggregation, or loss of material. Once dissolved, stability depends on solvent, concentration, and temperature, and solutions are usually treated as short-lived unless stability data support longer periods. Handling notes typically emphasise minimising time at ambient temperature.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular formula | C50H69N15O9 | Neutral form, mass near 1024.2 g/mol |
| Primary targets | MC1R, MC3R, MC4R, MC5R | Binding is non-selective across subtypes |
| Related compounds | Alpha-MSH, melanotan I, afamelanotide | Structurally or functionally related peptides |
| Common abbreviations | MT-II, MT-2 | Naming in the literature is not uniform |
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
==== MeSH E05.196.922 – titrimetry ==== MeSH E05.196.922.250 – colorimetry MeSH E05.196.922.375 – complement hemolytic activity assay MeSH E05.196.922.500 – conductometry MeSH E05.196.922.625 – neutralization tests MeSH E05.196.922.750 – potentiometry MeSH E05.196.922.875 – skin test end-point titration
According to the 2015–2016 Association of Research Libraries' "Spending by University Research Libraries" report, UA libraries are ranked as the 37th overall university library in North America (out of 114) for university investment. As of 2012, the UA's library system contains over six million print volumes, 1.1 million electronic books, and 74,000 electronic journals. The Main Library, opened in 1976, serves as the library system's reference, periodical, and administrative center; most of the main collections are housed here. The Main Library is on the southeast quadrant of campus near McKale Center and Arizona Stadium. In 2002, the Integrated Learning Center (ILC) was completed as a $20 million, 100,000-square-foot (10,000 m2) computer facility intended for use by incoming students. The ILC features classrooms, auditoriums, a courtyard with vending machines, and an expanded computer lab with several dozen workstations and 3D printing. Computers and 3D printing are available for use by the general public (with some restrictions) as well as by UA students, faculty and staff. The Arizona Health Sciences Library, built in 1996, is on the Health Sciences Center on the north end of campus and on the Phoenix Biomedical Campus, in the Health Sciences Education Building (HSEB). The library serves the Colleges of Medicine, Nursing, Pharmacy, Public Health, and Veterinary Medicine, the University of Arizona Health Network, and is a resource for health professionals and citizens across the state. An important part of the Main Library is the Special Collections library.
== Mechanism of action == Sodium hyaluronate functions as a tissue lubricant and is thought to play an important role in modulating the interactions between adjacent tissues. It forms a viscoelastic solution in water. Mechanical protection for tissues (iris, retina) and cell layers (corneal, endothelium, and epithelium) are provided by the high viscosity of the solution. Elasticity of the solution assists in absorbing mechanical stress and providing a protective buffer for tissues. In facilitating wound healing, it is thought that it acts as a protective transport vehicle, taking peptide growth factors and other structural proteins to a site of action. It is then enzymatically degraded and active proteins are released to promote tissue repair.
Sources: en.wikipedia.org
== Further reading == Kremyanskaya M, Ginzburg YZ, Hoffman R (March 2026). "Modulators of the hepcidin pathway in polycythemia vera and myelofibrosis". Blood. 147 (12): 1278–1288. doi:10.1182/blood.2025028643. PMID 41100735.
They were treated for about four years and gained 4-8 cm in adult height. Controversy has arisen as to whether all of these children were truly "short normal" children, since the average IGF1 was low. Approval of HGH for the treatment of this extreme degree of shortness led to an increase in the number of parents seeking its use to make otherwise normal children a little taller.
=== Hantzsch pyridine synthesis === The Hantzsch dihydropyridine synthesis employs two molecules of a 1,3-dicarbonyl compound (for example ethyl acetoacetate), together with an aldehyde and one molecule of ammonia. These components condense to form a symmetrical 1,4-dihydropyridine derivative, which undergoes aromatization by oxidation to yield a pyridine. A wide range of oxidizing agents is suitable for this final oxidation step; in some cases, exposure of the intermediate to air is sufficient. Alternatively, activated carbon with adsorbed oxygen or catalysts such as palladium or the enzyme laccase can be used to promote air oxidation. A one-pot reaction for pyridine synthesis based on the Hantzsch reaction starts from acetoacetic ester and an aldehyde. The reaction is performed under microwaves and in the presence of bentonite as an acidic catalyst. Ammonium nitrate serves both as an ammonia equivalent and as an oxidizing agent for the oxidation of the dihydropyridine intermediate. This method has been used as a basis for the combinatorial chemistry of pyridines to generate molecular libraries.
Sources: en.wikipedia.org
Smoking 20 cigarettes a day entails a higher risk, but not proportionately. If someone stops smoking, then these chances gradually decrease as the damage to their body is repaired. A year after quitting, the risk of contracting heart disease is half that of a continuing smoker. The health risks of smoking are not uniform across all smokers; risks vary according to the amount of tobacco smoked, with those who smoke more at greater risk. Smoking so-called "light" cigarettes does not reduce the risk.
== History == ATP was discovered in 1929 from muscle tissue by Karl Lohmann and Jendrassik and, independently, by Cyrus Fiske and Yellapragada Subba Rao of Harvard Medical School, both teams competing against each other to find an assay for phosphorus. It was proposed to be the intermediary between energy-yielding and energy-requiring reactions in cells by Fritz Albert Lipmann in 1941. He played a major role in establishing that ATP is the energy currency of a cell. It was first synthesized in the laboratory by Alexander Todd in 1948, and he was awarded the Nobel Prize in Chemistry in 1957 partly for this work. The 1978 Nobel Prize in Chemistry was awarded to Peter Dennis Mitchell for the discovery of the chemiosmotic mechanism of ATP synthesis. The 1997 Nobel Prize in Chemistry was divided, one half jointly to Paul D. Boyer and John E. Walker "for their elucidation of the enzymatic mechanism underlying the synthesis of adenosine triphosphate (ATP)" and the other half to Jens C. Skou "for the first discovery of an ion-transporting enzyme, Na+, K+ -ATPase."
Typical cyclodextrins are constituted by 6-8 glucopyranoside units. These subunits are linked by 1,4 glycosidic bonds. The cyclodextrins have toroidal shapes, with the larger and the smaller openings of the toroid exposing to the solvent secondary and primary hydroxyl groups respectively. Because of this arrangement, the interior of the toroids is considerably less hydrophilic than the aqueous environment and thus able to host hydrophobic molecules. In contrast, the exterior is sufficiently hydrophilic to impart cyclodextrins (or their complexes) water solubility. They are not soluble in typical organic solvents.
== Gene == The PPY gene encodes an unusually short protein precursor of 95 amino acids in length. This precursor is cleaved to produce the signal peptide, the pancreatic polypeptide, the pancreatic icosapeptide, and a 5- to 7- amino-acid oligopeptide.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.
Activation of MC1R increases pigment synthesis independently of ultraviolet exposure, which is the mechanism usually cited for darkening without sun exposure. Ultraviolet light still influences skin response through separate biological pathways.
Because the peptide binds several melanocortin receptor subtypes, its effects are not confined to pigmentation. This complicates interpretation of both intended and unintended outcomes reported in studies.
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.